Orano SA
Long-cycle B2B contracts with nuclear utilities across the full fuel cycle (front end: mining/conversion/enrichment; back end: recycling, packaging, dismantling), sold under multi-year contracts producing a backlog of ~7 years of revenue; plus emerging nuclear-medicine unit (Orano Med)
Values are EUR billions (EUR-USD ~1.10 per the dossier's sourceNote; multiply by ~1.10 for USD). Orano is state-owned, not venture-backed: these are the only disclosed real-money equity events since the 2017 creation from New AREVA. The 2018 point is the only third-party (arm's-length-adjacent) price; the 2017 and 2024 points are French-State subscriptions. The trajectory (EUR ~5bn 2018 -> EUR ~9bn implied 2024) is consistent with the dossier's illustrative base-case equity range of EUR 7.5-9.5bn.
Earnings, margins, COGS & capex
FY2025 (published Feb 20, 2026): revenue EUR 5,138M, EBITDA EUR 1,382M (26.9%), operating income EUR 516M, reported net income group share +EUR 404M but ADJUSTED net income of -EUR 25M (penalized by revisions to end-of-lifecycle estimates; the reported figure benefits from favorable actuarial effects and a high return on earmarked assets). Optically down vs 2024 because 2024 included exceptional Japanese-utilities back-end contracts (2024: revenue EUR 5,874M, EBITDA EUR 2,067M, net income EUR 633M); restated for that one-off and the Niger loss of control, the business progressed. Backlog EUR 34,239M (~7 years of revenue; down EUR 1.7bn mainly on USD weakness); order intake EUR 4,154M, 76% outside France. Balance sheet at its strongest: net debt EUR 0.44bn. Guidance: 2026 revenue anchored above EUR 5bn, EBITDA margin 23-25%, financial leverage <= 1.5x net debt/EBITDA at end-2028 as the capex wave (GBII extension, Aval du Futur, US plant) ramps.
Revenue trend
Margins
normalizing from one-off-inflated 2024; guided 23-25% for 2026
down - Back End op income swung to -EUR 224M (vs +EUR 616M) on the 2024 one-off base plus additional end-of-lifecycle provisions; Mining op income up to EUR 353M (vs EUR 122M), Front End up to EUR 468M (vs EUR 425M)
reported net income +EUR 404M flattered by favorable actuarial effects and earmarked-asset returns
COGS structure
Not disclosed as a line item. Cost structure: uranium mining cash costs (Kazakhstan/Canada JVs, Uzbekistan ramp), conversion/enrichment plant operating costs (energy-intensive centrifuge cascades at Tricastin), recycling plant operations (La Hague/Melox), plus very large long-term end-of-lifecycle (decommissioning/waste) provisions whose estimate and discount-rate revisions swing operating income - the dominant 2025 negative.
Capex
Net capex EUR 1,269M FY2025 (vs EUR 980M FY2024, +29.5%), mostly the Georges Besse II enrichment capacity extension (+30%+ capacity / 2.5M SWU, ~EUR 1.7bn program, initial production 2028, full commissioning 2030), plus increased Mining and nuclear-medicine capex. Ahead: 'Aval du Futur' recycling-plant renewal (multi-decade; ramp-up began 2025) and the ~$5bn IKE enrichment plant in Oak Ridge, TN with $900M DOE funding (awarded Jan 5, 2026) - capex intensity stays elevated for years.
Latest earnings
Company framed FY2025 as '2025 results above expectations' (vs its own guidance); no analyst consensus exists (unlisted)
2026 revenue anchored above EUR 5bn; 2026 EBITDA margin 23-25%; financial leverage (net debt/EBITDA) <= 1.5x at end-2028; note the shift to a leverage objective as capex accelerates, which the company links to the deleveraging achieved since its creation
- Backlog (Dec 31, 2025)
- EUR 34,239M (~7 years of revenue; EUR 35.9bn end-2024)
- Order intake FY2025
- EUR 4,154M (76% outside France)
- Net financial debt
- EUR 0.44bn (vs EUR 0.78bn end-2024)
- Net capex FY2025
- EUR 1,269M (+29.5%)
- Segment revenue FY2025
- Mining EUR 1,492M; Front End EUR 1,250M; Back End EUR 2,352M; Corporate/other incl. Orano Med EUR 44M
- End-of-lifecycle coverage
- 97.3% regulatory coverage rate at end-2025 (97.0% end-2024)
- Employees
- ~18,500
Growth drivers
- Western enrichment/conversion capacity shortage as the US bans Russian enriched uranium (ban in force since Aug 2024; DOE waivers expire end-2027, full effect from 2028) - Orano is one of only two Western enrichers at scale (with Urenco)
- US expansion — IKE enrichment plant at Oak Ridge, TN (~$5bn; $900M DOE funding Jan 2026; environmental report to NRC Feb 2026, license application accepted for NRC review May 2026; LEU production targeted 2031)
- Georges Besse II capacity extension (+30%+, 2.5M SWU) with initial production from 2028
- Mining growth — South Djengeldi via the Nurlikum Mining JV in Uzbekistan (Orano 45%, Navoiyuran 45%, ITOCHU the remainder) targeting ~500 tU/yr on average for 10 years; Canada and Kazakhstan JVs
- Aval du Futur back-end renewal program (ramp-up began 2025) securing decades of French recycling revenue
- Orano Med (targeted-alpha-therapy radiopharma) — Sanofi took a stake in Orano Med Theranostics (agreements Oct 2024, cash received in 2025)
- EUR 34.2bn backlog (~7 years of revenue) giving high revenue visibility
Bull & bear
Orano is the West's most complete answer to a structurally undersupplied, de-Russifying nuclear fuel market: near-monopoly-adjacent enrichment economics, a 7-year backlog, its cleanest balance sheet ever, and a US beachhead part-funded by the DOE - with radiopharma optionality on top.
- Structural scarcity: only Urenco and Orano can supply Western enrichment at scale; the US ban on Russian enriched uranium (full effect 2028) and utilities' 'no-Russia' procurement create a decade of pricing power - 2025 order intake of EUR 4.15bn (76% export) shows it
- The $900M DOE award (Jan 5, 2026) for the ~$5bn Oak Ridge IKE plant de-risks entry into the largest enrichment market and diversifies away from EDF/France; NRC licensing is already moving (application accepted for review May 2026)
- Backlog EUR 34.2bn locks ~7 years of revenue at contemporary (high) SWU/conversion prices; 2026 guidance of >EUR 5bn revenue at 23-25% EBITDA margin is a floor, not a stretch
- Balance sheet inflection: net debt down to EUR 0.44bn with EUR 2.1bn cash and cash-management assets plus undrawn EUR 880M syndicated facility and EUR 400M EIB line - the capex wave is fundable without distress
- Mining replacement executed: Uzbekistan South Djengeldi (45% of the Nurlikum JV, with Navoiyuran and ITOCHU) plus Kazakh/Canadian JVs offset Niger; the ICSID ruling preserves the legal claim on SOMAIR uranium
- Free option value: Orano Med's Sanofi-validated targeted alpha therapy platform and HALEU/SMR fuel positioning cost the thesis nothing today
A state-controlled, capex-devouring industrial with negative adjusted earnings, unrecoverable Niger losses, and results that depend on discount-rate accounting - where the bull case requires flawless execution of three simultaneous nuclear mega-projects, a genre with a dismal cost-overrun history.
- Adjusted net income was NEGATIVE in FY2025 (-EUR 25M vs +EUR 597M in 2024): strip the actuarial gains and earmarked-asset returns and the industrial machine barely earns its cost of capital
- Capex intensity ~25% of revenue and rising - GBII extension, ~$5bn IKE, and the multi-decade Aval du Futur renewal mean FCF is structurally mortgaged; management itself introduced a leverage cap (<=1.5x by end-2028) into its outlook, a tell that borrowing is coming
- Niger is a realized loss, not a risk: SOMAIR seized; the ICSID win orders Niger not to sell the uranium but offers no practical recovery path from a sanctioned junta
- Back End segment op income of -EUR 224M and repeated end-of-lifecycle estimate revisions show the recycling franchise's tail liabilities keep repricing against Orano
- Scarcity pricing is policy-made and policy-unmade: any US-Russia normalization or waiver extension re-floods the SWU market where Rosatom retains the world's largest, lowest-cost capacity
- Governance discount is permanent: a 90.33% state owner optimizes for French energy sovereignty and employment, not minority returns - and 2024's growth proved partly one-off (Japanese utilities contracts), showing the earnings base is lumpier than headline trends suggest
What it is worth
No market valuation exists (unlisted, 90.33% French State). Two disclosed real-money anchors: (1) the Oct 2024 EUR 300M capital increase was priced at EUR 32.80/share (EUR 0.50 par + EUR 32.30 premium), which across ~273M post-money shares implies ~EUR 9bn equity - subscribed solely by the French State, so not an arm's-length market test; (2) JNFL+MHI paid EUR 500M for 10% in 2018 (~EUR 5bn equity then; dated). Illustrative EV/EBITDA comps: Western fuel-cycle scarcity names (CCJ, LEU) trade at rich double-digit EV/EBITDA, but Orano warrants a large discount for state control, negative adjusted earnings, the nuclear liability tail and the capex burden - a 5-9x range on normalized EBITDA of ~EUR 1.2-1.4bn is the defensible frame, and it brackets the 2024 issue-price anchor.
~EUR 5-6bn EV (4-5x EUR ~1.2bn EBITDA on Russia re-entry, project overruns, or provision shocks) -> ~EUR 4.5-5.5bn equity, near the 2018 JNFL/MHI reference (illustrative)
~EUR 8-10bn EV (6-7x EUR ~1.3bn EBITDA) -> ~EUR 7.5-9.5bn equity (illustrative; consistent with the ~EUR 9bn implied by the Oct 2024 issue price)
~EUR 11-13bn EV (8-9x EUR ~1.4bn normalized EBITDA if US expansion executes and scarcity pricing persists) less ~EUR 0.4bn net debt -> ~EUR 10.5-12.5bn equity (illustrative)
Any figure is analytical inference, not a disclosed group valuation. End-of-lifecycle liabilities (97.3% covered by earmarked assets) must be treated as debt-like in any EV bridge. Not financial advice; there is no public security to buy - only Orano bonds trade (Euronext Paris).
SWOT
Strengths
- One of only two Western-owned enrichment suppliers (with Urenco) at a moment of forced de-Russification of the fuel cycle
- Full fuel-cycle integration (mining -> conversion -> enrichment -> recycling) unique outside Russia/China; La Hague is the world's largest commercial recycling complex
- EUR 34.2bn backlog, ~7 years of revenue visibility, 76% of 2025 order intake export
- Net debt at its lowest level (EUR 0.44bn) plus sovereign backing from a 90.33% French-State owner
- Anchor customer EDF plus diversified US/Asian utility base — ICSID arbitration win vs Niger (Sept 23, 2025) protecting SOMAIR uranium rights
Weaknesses
- Adjusted net income negative in FY2025 (-EUR 25M) — end-of-lifecycle estimate revisions repeatedly eat operating results; Back End op income -EUR 224M
- Massive, rising capex (EUR 1.27bn in 2025, ~$5bn US plant, Aval du Futur ahead) pressuring free cash flow for years
- Lost control of Niger mining entities (SOMAIR seized by the junta) - a top-3 historical uranium source deconsolidated
- State ownership constrains capital allocation and commercial agility; no equity currency for M&A
- Revenue lumpy and contract-driven (2024 vs 2025 swing shows one-off dependence); reported net income driven by actuarial/discount-rate noise
Opportunities
- US Russian-uranium import ban (waivers expire end-2027) plus the $900M DOE award for the Oak Ridge IKE plant - structural share gain in the world's largest enrichment market
- AI/datacenter-driven nuclear renaissance — plant life extensions, restarts and new builds lifting long-term SWU/UF6/uranium demand
- Enrichment scarcity pricing — SWU and conversion prices near record levels lock in high-margin long-term contracts
- Uzbekistan (South Djengeldi ~500 tU/yr) and other mining diversification replacing Niger
- HALEU for SMRs/advanced reactors — used-fuel recycling interest spreading (Calogena CAL30 partnership, ULC-Energy spent-fuel cooperation, both Nov 2025)
- Orano Med radiopharma optionality validated by Sanofi investment
Threats
- Sahel resource nationalism — expropriation of Niger assets; ICSID enforcement against a junta is slow and uncertain
- Rosatom/Tenex re-entry if the sanctions regime softens post-conflict would collapse Western scarcity pricing (context: CNNC/CGN also expanding fuel-cycle exports)
- Execution/overrun risk on simultaneous mega-projects (GBII extension, IKE, Aval du Futur) - the sector's track record on nuclear construction is poor
- Uranium/SWU price cyclicality: today's contracts priced at highs could meet a softer spot market
- French politics/budget — state shareholder priorities and any weakening of state support for Aval du Futur funding
- Long-tail nuclear liabilities — estimate and discount-rate moves on multi-billion-euro end-of-lifecycle commitments swing results and could require cash top-ups
Moats, dependencies & bottlenecks
Moats
Regulatory/technology barrier in enrichment (centrifuge technology, ETC JV licensing, nuclear licensing) New entrants need a decade and billions; only Urenco shares the Western position (Centrus is rebuilding US capacity from a small base)
Only commercial-scale Western used-fuel recycler; irreplaceable French back-end franchise, renewed via Aval du Futur - but it carries the liability tail
EUR 34.2bn backlog with switching costs typical of fuel-cycle qualification
French State at 90.33% is both a moat (implicit support, EIB access) and a constraint
Only non-Russian/non-Chinese player spanning mining to recycling; supports bundled utility deals
Dependencies
ownership/customer Capital increases, Aval du Futur funding and back-end economics all route through Paris; EDF is itself 100% state-owned
Kazatomprom/Kazakhstan JVs (KATCO) and Canadian JVs (Cameco-operated Cigar Lake) Post-Niger, mining output leans on Kazakhstan (Russia-adjacent logistics) and Canada
regulatory/funding IKE needs the DOE funding definitized and an NRC license (application accepted for review May 2026; full facility licensing still ahead); US policy continuity matters
Japanese partners JNFL and MHI (4.83% each) and Japanese utilities shareholder/customer 2024's exceptional back-end revenue came from Japanese utilities; Rokkasho support ties continue
Centrifuge cascades are power-hungry; Tricastin sits next to EDF capacity
South Djengeldi is the flagship Niger replacement; single-country execution risk
Advantages
- Scarcity-positioned Western enricher exactly when demand (AI-driven nuclear expansion) meets a supply-side embargo on Russia
- 7-year revenue visibility from EUR 34.2bn backlog priced in a strong market
- Net debt at its lowest level since Orano's 2017 creation, plus sovereign and EIB funding channels
- Unique recycling know-how increasingly relevant as countries reconsider used-fuel strategies
- DOE-backed US expansion with $900M public funding lowering entry cost
Weaknesses
- Negative adjusted earnings in FY2025; profitability hostage to end-of-lifecycle provision accounting
- No public equity, no market discipline, no currency for M&A; minority economics subordinate to French policy
- Realized geopolitical loss in Niger with weak practical recourse
- Structurally heavy and rising capex for the rest of the decade
- Revenue lumpiness from long-cycle contracts (2024 one-off distorts trends)
Bottlenecks
- Enrichment capacity — GBII extension adds +30%+ (2.5M SWU) with initial production 2028 and full commissioning 2030; IKE output targeted from 2031 - Orano cannot fully monetize the scarcity window until new cascades spin
- Conversion capacity (Philippe Coste plant) is a global chokepoint shared with Cameco/ConverDyn/Westinghouse Springfields
- Skilled nuclear workforce and centrifuge manufacturing throughput (ETC JV with Urenco) limit expansion speed
- Capital: three simultaneous mega-programs compete for the same balance sheet; leverage objective of <=1.5x at end-2028 bounds ambition
- Uranium sourcing post-Niger until Uzbekistan/other projects fully ramp
Top signals & trends
Top signals
US beachhead de-risked and licensing on an accelerated track; LEU production targeted 2031
Tribunal ordered Niger not to sell or transfer the retained uranium; enforcement against the junta remains uncertain
Strong today, but adding a leverage objective telegraphs heavy borrowing for the capex wave
Core-earnings quality issue beneath a positive reported +EUR 404M
External validation of the radiopharma unit
Concrete Niger replacement volume
FX translation, not demand; order intake still EUR 4.15bn
Trends
strongly positive · Direct share gain for the only two Western enrichers
Lifts uranium, conversion and SWU demand across Orano's whole chain
Orano partnerships with Calogena (CAL30 30 MWth SMR, Nov 2025) and ULC-Energy (spent-fuel treatment/storage/transport, Nov 2025); HALEU is a future product line
Niger already lost; Kazakhstan/Uzbekistan concentration is the residual exposure
Plays to La Hague expertise; Aval du Futur renews it
2025 Front End op income rose on price/mix, production and impairment reversals in Conversion
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
JV partner in Kazakh uranium mining (KATCO)
45/45 JV partner in Nurlikum Mining (South Djengeldi uranium)
JV with Urenco) Centrifuge technology and manufacturing for GBII
French nuclear engineering group; partner on Orano projects (WNE 2025 agreements)
Electricity supply for enrichment operations; also the anchor customer
Anchor customer across the full cycle including La Hague recycling
Largest US nuclear fleet operator; representative of the US enrichment/uranium customer base Orano serves and targets with IKE
US utility fuel buyer
Representative of the Japanese utilities that drove the exceptional 2024 back-end contracts
Government customer/funder ($900M IKE funding; cleanup and HALEU programs)
Anglo-German-Dutch state-owned enricher; the other Western SWU supplier and Orano's closest peer (also unlisted)
Largest listed Western uranium miner, 49% owner of Westinghouse; competes in mining/conversion and fuel services
US enricher rebuilding domestic capacity, first mover in HALEU; direct rival for DOE support and US utility SWU contracts
World's largest, lowest-cost uranium miner; both partner (KATCO JV) and mining competitor
World's largest enrichment capacity; the displaced incumbent whose potential re-entry is the biggest pricing risk - context only
US nuclear components and fuel services; competes in government fuel-cycle work
Fuel fabrication and conversion (Springfields); competes in fuel supply to Western utilities
Expanding Chinese fuel-cycle exports in non-aligned markets - analytical context only, not an investable comparison here
Laser enrichment (GLE, with Cameco) targeting late-decade US capacity; emerging technology threat